ArticleJournal of neuro-oncology2011
Differential kinetics of α-[¹¹C]methyl-L-tryptophan on PET in low-grade brain tumors.
Article in Journal of neuro-oncology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 40 citations in OpenAlex.
- Quantitative PET imaging of tryptophan accumulation in gliomas and remote cortex: correlation with tumor proliferative activity.Clinical nuclear medicine · 2012Trial
- Preliminary Results on the Added Value of Parametric Images Derived fromMolecular imaging and biology · 2026Article
- Tryptophan Kynurenine Pathway-Based Imaging Agents for Brain Disorders and Oncology-From Bench to Bedside.Biomolecules · 2025Review
- PET Imaging of Neurofibromatosis Type 1 with a Fluorine-18 Labeled Tryptophan Radiotracer.Pharmaceuticals (Basel, Switzerland) · 2024Article
- Automated radiosynthesis of 1-(2-[Journal of labelled compounds & radiopharmaceuticals · 2023Article
- Review
- Molecular Imaging of Brain Tumor-Associated Epilepsy.Diagnostics (Basel, Switzerland) · 2020Review
- PET imaging of medulloblastoma with anScientific reports · 2020Article
- The Emerging Role of Amino Acid PET in Neuro-Oncology.Bioengineering (Basel, Switzerland) · 2018Review
- Assessment of Tryptophan Uptake and Kinetics Using 1-(2-18F-Fluoroethyl)-l-Tryptophan and α-11C-Methyl-l-Tryptophan PET Imaging in Mice Implanted with Patient-Derived Brain Tumor Xenografts.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2017Article
- Carbon-11 and Fluorine-18 Labeled Amino Acid Tracers for Positron Emission Tomography Imaging of Tumors.Frontiers in chemistry · 2017Review
- PET and SPECT studies in children with hemispheric low-grade gliomas.Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery · 2016Review
- Tryptophan PET Imaging of the Kynurenine Pathway in Patient-Derived Xenograft Models of Glioblastoma.Molecular imaging · 2016Article
- Imaging cerebral tryptophan metabolism in brain tumor-associated depression.EJNMMI research · 2015Article
- Molecular imaging correlates of tryptophan metabolism via the kynurenine pathway in human meningiomas.Neuro-oncology · 2015Article
- N (1)-Fluoroalkyltryptophan Analogues: Synthesis and in vitro Study as Potential Substrates for Indoleamine 2,3-Dioxygenase.ACS medicinal chemistry letters · 2015Article
- SPECT and PET serve as molecular imaging techniques and in vivo biomarkers for brain metastases.International journal of molecular sciences · 2014Review
- Comparison of amino acid positron emission tomographic radiotracers for molecular imaging of primary and metastatic brain tumors.Molecular imaging · 2014Review
- Progress on the diagnosis and evaluation of brain tumors.Cancer imaging : the official publication of the International Cancer Imaging Society · 2013Review
- In vivo metabolism of tryptophan in meningiomas is mediated by indoleamine 2,3-dioxygenase 1.Cancer biology & therapy · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 1 country.
Funding
Abstract
Increased tryptophan metabolism via the kynurenine pathway is a major mechanism of tumor immuno-resistance. α-[(11)C]Methyl-L: -tryptophan (AMT) is a positron emission tomography (PET) tracer for tryptophan catabolism, and increased AMT uptake has been demonstrated in brain tumors. In this study we evaluated the use of AMT PET for detection of low-grade gliomas and glioneuronal tumors, and determined if kinetic parameters of AMT uptake can differentiate among tumor types. AMT PET images were obtained in 23 patients with newly diagnosed low-grade brain tumors (WHO grade II gliomas and WHO grade I dysembryoplastic neuroepithelial tumors [DNETs]). Kinetic variables, including the unidirectional uptake rate (K-complex) and volume of distribution (VD; which characterizes tracer transport), were measured using a graphical approach from tumor dynamic PET and blood-input data, and metabolic rates ([Formula: see text]) were also calculated. These values as well as tumor/cortex ratios were compared across tumor types. AMT PET showed increased tumor/cortex K-complex (n = 16) and/or VD ratios (n = 15) in 21/23 patients (91%), including 11/13 tumors with no gadolinium enhancement on MRI. No increases in AMT were seen in an oligodendroglioma and a DNET. Astrocytomas and oligoastrocytomas showed higher [Formula: see text] tumor/cortex ratios (1.66 ± 0.46) than oligodendrogliomas (0.96 ± 0.21; P = 0.001) and DNETs (0.75 ± 0.39; P < 0.001). These results demonstrate that AMT PET identifies most low-grade gliomas and DNETs by high uptake, even if these tumors are not contrast-enhancing on MRI. Kinetic analysis of AMT uptake shows significantly higher tumor/cortex tryptophan metabolic ratios in astrocytomas and oligoastrocytomas in comparison with oligodendrogliomas and DNETs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.